Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

April 2019 | 296 pages | ID: NB58190C0D7EN
Global Markets Direct

Abstracts

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 21, 13, 1, 31 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Akcea Therapeutics Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ardelyx Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by BioElectron Technology Corp, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Boehringer Ingelheim GmbH, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cadila Healthcare Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Carmot Therapeutics Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eli Lilly and Co, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Evgen Pharma Plc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by GemVax & KAEL Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HemoShear Therapeutics, LLC, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Global Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inventiva, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ionis Pharmaceuticals Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kinomedica Pty Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kowa Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by MallInckrodt Plc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Mina Therapeutics Ltd, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H1 2019
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NuSirt Biopharma Inc, H1 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019

COMPANIES MENTIONED

Akcea Therapeutics Inc
Ardelyx Inc
AstraZeneca Plc
Betagenon AB
BioElectron Technology Corp
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Cerenis Therapeutics Holding SA
Corcept Therapeutics Inc
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Eternygen GmbH
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
GemVax & KAEL Co Ltd
Gilead Sciences Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics, LLC
Huons Global Co Ltd
Immuron Ltd
Inventiva
Ionis Pharmaceuticals Inc
Kinomedica Pty Ltd
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
MallInckrodt Plc
Metacrine Inc
Mina Therapeutics Ltd
Novartis AG
NuSirt Biopharma Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Renova Therapeutics Inc
Ritter Pharmaceuticals Inc
Sancilio & Company Inc
Shenzhen HighTide Biopharmaceutical Ltd
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
Theratechnologies Inc
Tiziana Life Sciences Plc
Viking Therapeutics Inc